Evidence map›Paper›PMID 40071076›Full record

ArticleSovremennye tekhnologii v meditsine2025

Efficacy Evaluation of "Enhanced" Natural Killers with

D V Yuzhakova, D A Sachkova, M V Shirmanova, V I Shcheslavskiy, A M Mozherov, E B Dashinimaev, V P Baklaushev, G M Yusubalieva

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Sovremennye tekhnologii v meditsine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

D V YuzhakovaPhD, Senior Researcher, Laboratory of Genomics of Adaptive Antitumor Immunity, Research Institute of Experimental Oncology and Biomedical Technologies; Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia; Senior Researcher, Laboratory of Cellular Technologies; Federal Scientific and Clinical Center of the Federal Medical Biological Agency of Russia, 28 Orekhovy Blvd., Moscow, 115682, Russia.
D A SachkovaLaboratory Assistant, Laboratory of Fluorescent Bioimaging, Research Institute of Experimental Oncology and Biomedical Technologies; Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia; PhD Student, Department of Biophysics, Institute of Biology and Biomedicine; National Research Lobachevsky State University of Nizhny Novgorod, 23 Prospekt Gagarina, Nizhny Novgorod, 603022, Russia.
M V ShirmanovaPhD, Deputy Director for Science, Research Institute of Experimental Oncology and Biomedical Technologies; Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.
V I ShcheslavskiyDSc, Head of the Laboratory of Optical Spectroscopy and Microscopy, Research Institute of Experimental Oncology and Biomedical Technologies; Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.
A M MozherovJunior Researcher, Laboratory of Optical Spectroscopy and Microscopy, Research Institute of Experimental Oncology and Biomedical Technologies; Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.
E B DashinimaevPhD, Acting Head of the Laboratory of Cellular Reprogramming, Research Institute of Translational Medicine; Pirogov Russian National Research Medical University, 1, Bldg. 6, Ostrovityanova St., Moscow, 117513, Russia; Head of the Laboratory of Bioengineering, Research Institute of Molecular and Cellular Medicine; Peoples' Friendship University of Russia named after Patrice Lumumba, 6 Miklukho-Maklaya St., Moscow, 117198, Russia.
V P BaklaushevMD, DSc, Head of the Biomedical Research Center; Federal Scientific and Clinical Center of the Federal Medical Biological Agency of Russia, 28 Orekhovy Blvd., Moscow, 115682, Russia; Head of the Cell Therapy Development Department; Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency of Russia, 1, Bldg. 10, Ostrovityanova St., Moscow, 117513, Russia; Head of the Laboratory of Molecular Regeneration Mechanisms; Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences, 32 Vavilov St., Moscow, 119991, Russia.
G M YusubalievaMD, PhD, Senior Researcher, Laboratory of Cell Technologies; Federal Scientific and Clinical Center of the Federal Medical Biological Agency of Russia, 28 Orekhovy Blvd., Moscow, 115682, Russia; Head of the Laboratory of Solid Tumor Immunotherapy; Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency of Russia, 1, Bldg. 10, Ostrovityanova St., Moscow, 117513, Russia; Senior Researcher, Laboratory of Molecular Regeneration Mechanisms; Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences, 32 Vavilov St., Moscow, 119991, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the alternative approaches to glioblastoma treatment is cellular immunotherapy based on natural killer cells (NK cells). To enhance their cytotoxic effect on tumor cells, new NK cell lines are being created using genetic engineering techniques. Materials and Methods: The study used a primary culture of GBM7-Luc2-mKate2 human glioblastoma, a line of YT (YTwt) wildtype human NK cells, as well as lines created by us with overexpression of VAV1 protein with either Results: It was found that autofluorescence attenuation parameters of NAD(P)H coenzyme in human glioblastoma cells change significantly when exposed to both YT-Vav1 Conclusion: The data obtained on enhanced cytotoxic activity of new modified NK cell lines against human glioblastoma spheroids are important to understand interaction mechanisms between tumor and immune cells and the development of glioblastoma adoptive cell therapy.

Indexed as

Brain NeoplasmsGlioblastomaKiller Cells, NaturalSpheroids, CellularCell Line, TumorCell SurvivalGene Knockout TechniquesHumansFLIMimmunotherapymetabolic imagingNAD(P)HNK cellspatient’s glioblastomatumor spheroids

Identifiers

PMID40071076
PMCPMC11892565

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.